Inventor
WEEDEN TIMOTHY
US54 patents
Patents
50 patentsUS11286305B2Mar 29, 2022
Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA
DYNE THERAPEUTICS INC64 citations99
US11111309B2Sep 7, 2021
Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4
DYNE THERAPEUTICS INC65 citations99
US11833217B2Dec 5, 2023
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC30 citations98
US11795233B2Oct 24, 2023
Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide
DYNE THERAPEUTICS INC32 citations98
US11795234B2Oct 24, 2023
Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
DYNE THERAPEUTICS INC32 citations98
US11787869B2Oct 17, 2023
Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness
DYNE THERAPEUTICS INC32 citations98
US11771776B2Oct 3, 2023
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC32 citations98
US11759525B1Sep 19, 2023
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC32 citations98
US11679161B2Jun 20, 2023
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC38 citations98
US11672872B2Jun 13, 2023
Anti-transferrin receptor antibody and uses thereof
DYNE THERAPEUTICS INC37 citations98
US11648318B2May 16, 2023
Anti-transferrin receptor (TFR) antibody and uses thereof
DYNE THERAPEUTICS INC37 citations98
US11638761B2May 2, 2023
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC47 citations98
US11633496B2Apr 25, 2023
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC36 citations98
US11518816B2Dec 6, 2022
Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC46 citations98
US11497815B2Nov 15, 2022
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC46 citations98
US11390682B2Jul 19, 2022
Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy
DYNE THERAPEUTICS INC48 citations98
US11369689B2Jun 28, 2022
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC48 citations98
US11248056B1Feb 15, 2022
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC50 citations98
US11168141B2Nov 9, 2021
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC53 citations98
US12263225B2Apr 1, 2025
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
DYNE THERAPEUTICS INC11 citations95
US12173078B2Dec 24, 2024
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
DYNE THERAPEUTICS INC14 citations95
US12173079B2Dec 24, 2024
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
DYNE THERAPEUTICS INC14 citations95
US12097263B2Sep 24, 2024
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC18 citations95
US12018087B2Jun 25, 2024
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
DYNE THERAPEUTICS INC23 citations95
US12012460B2Jun 18, 2024
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
DYNE THERAPEUTICS INC22 citations95
US12005124B2Jun 11, 2024
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC23 citations95
US11911484B2Feb 27, 2024
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC28 citations95
US12239717B2Mar 4, 2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC13 citations94
US12239716B2Mar 4, 2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC13 citations94
US12144868B2Nov 19, 2024
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC14 citations94
US12144867B2Nov 19, 2024
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC14 citations94
US12102687B2Oct 1, 2024
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC17 citations94
US11986537B2May 21, 2024
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC24 citations94
US11969475B2Apr 30, 2024
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC25 citations94
US11844843B2Dec 19, 2023
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC30 citations94
US11839660B2Dec 12, 2023
Anti-transferrin receptor antibody and uses thereof
DYNE THERAPEUTICS INC30 citations94
US11633498B2Apr 25, 2023
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC37 citations94
US11931421B2Mar 19, 2024
Muscle targeting complexes and formulations for treating myotonic dystrophy
DYNE THERAPEUTICS INC26 citations92
US12329824B1Jun 17, 2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies
DYNE THERAPEUTICS INC4 citations86
US12325753B2Jun 10, 2025
Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy
DYNE THERAPEUTICS INC5 citations86
US12319743B2Jun 3, 2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
DYNE THERAPEUTICS INC5 citations86
US12280122B2Apr 22, 2025
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC5 citations86
US12128109B2Oct 29, 2024
Muscle targeting complexes and formulations for treating dystrophinopathies
DYNE THERAPEUTICS INC17 citations82
US12370264B1Jul 29, 2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
DYNE THERAPEUTICS INC2 citations75
US12357703B2Jul 15, 2025
Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping
DYNE THERAPEUTICS INC2 citations75
US12329825B1Jun 17, 2025
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
DYNE THERAPEUTICS INC4 citations75
US12496352B2Dec 16, 2025
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
DYNE THERAPEUTICS INC0 citations63
US12478687B2Nov 25, 2025
United states
DYNE THERAPEUTICS INC0 citations63
US12460011B2Nov 4, 2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject
DYNE THERAPEUTICS INC0 citations63
US12428487B2Sep 30, 2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject
DYNE THERAPEUTICS INC0 citations63
Showing the top 50 of 54 patents by PatentIndex Score.